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Dex on the propagation of cortical spreading depression (CSD), and tested the action of
vitamins C and E against the effect of Dex. Five groups of Wistar rats received, respectively:
[1] no treatment (Naïve); [2] Vehicle (V); [3] tapering doses of Dex (Dex; 0.5 mg/kg, 0.3 mg/kg,
and 0.1 mg/kg) on postnatal day (PND) 1–3; [4] Dex plus 200 mg/kg vitamin C and 100 mg/kg
vitamin E (DexCE); [5] only vitamins C and E (CE). Vehicle and vitamins were administered on
PND 1–6. CSD was recorded after the pups reached maturity (PND 60–70). The Dex-treated
group presented with higher CSD velocities (mean values7SD, in mm/min: 4.147
0.22, n¼10) compared with the control groups (Naïve: 3.5270.13, n¼8; V: 3.5770.18, n¼10;
CE: 3.5170.24, n¼10; po0.05 for all). Vitamins C and E antagonized this effect (DexCE group;
CSD velocity: 3.4370.12, n¼9). No intergroup difference was observed concerning
P-wave amplitude and duration. In all groups, after the cortex underwent CSD, the electro-
corticogram (ECoG) amplitude increased approximately 50% compared with the baseline
amplitude for the same animal (CSD-induced ECoG potentiation); however, no intergroup
difference was observed. Data suggest that coadministration of antioxidant vitamins with
Dex may be a helpful therapeutic strategy to reduce brain adverse effects of dexamethasone.
& 2014 Elsevier B.V. All rights reserved.5
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Dexamethasone is a synthetic glucocorticoid hormone that is
largely applied to preterm infants to prevent or treat chronic
lung diseases (Choi et al., 2004; Doyle et al., 2014a, 2014b).However, neonatal treatment with glucocorticoids can produce
unwanted side effects in the developing nervous system of
children (Hitzert et al., 2014; Shinwell et al., 2000; Stark et al.,
2001). Evidence from laboratory animals also indicates such
adverse effects (Bhatt et al., 2013; Duksal et al., 2009;
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Neal et al., 2003; Sze et al., 2013; Zuloaga et al., 2011). These
reports address the brain effects of dexamethasone on beha-
vioral, biochemical, and morphological parameters. However,
some other studies have demonstrated electrophysiological
changes in animals previously treated with dexamethasone,
including the appearance (Davidson et al., 2011) or modulation
of epileptiform activity (Yılmaz et al., 2014). Electrophysiological
alterations also include the modulation of synaptic plasticity-
dependent phenomena, such as long-term potentiation (LTP)
(Kamphuis et al., 2003; Lin et al., 2006; Wang et al., 2010). In this
scenario, experimental investigation based on electrophysiolo-
gical phenomena related to epilepsy and LTP is highly desirable.
This is the case regarding the phenomenon known as cortical
spreading depression (CSD), which has been studied by our
group (Batista-de-Oliveira et al., 2012a; Torrente et al., 2014b; see
Guedes, 2011 for a review) and by others (Footitt and Newberry,
1998; Dreier, 2011).
CSD has been experimentally described as a reversible and
propagated wave of reduction of the spontaneous electrical
activity of the cerebral cortex (Leão, 1944). This phenomenon
occurs in response to electrical, chemical, or mechanical
stimulation applied to one point of the cortical surface.
Simultaneously with the depression of brain activity, a slow
direct current (DC) potential change of the tissue has been
described (Leão, 1947). CSD has been widely used to evaluate
brain processes that depend on neural excitability (Batista-
de-Oliveira et al., 2012b; Guedes et al., 2005; Lima et al., 2013),
and a causal association between CSD and an LTP-like
potentiation of spontaneous and evoked cortical electrical
activity has been demonstrated both in vitro (Footitt and
Newberry, 1998) and in vivo (Faraguna et al., 2010; Guedes
et al., 2005; Souza et al., 2011).
Dexamethasone increases the presence of reactive oxygen
species (ROS) in cultured hippocampus and cerebral cortex
(McIntosh and Sapolsky, 1996), and reduces the basal activity
of brain antioxidant enzymes (McIntosh et al., 1998). Con-
sidering the hypothesis that most of the adverse effects of
dexamethasone are caused by oxidative stress, studies have
employed the antioxidant vitamins C and E to counteract the
adverse effects of this synthetic hormone (Camm et al., 2011;
Herrera et al., 2010; Niu et al., 2013; Williams et al., 2012).
These vitamins are able to minimize neuronal loss, as well asTable 1 – Body weights of the ﬁve experimental groups of rats
antioxidant vitamins (CE), or both (DexCE). Two additional con
these drugs were dissolved (V) or received no treatment (Naïv
Body weight (g)
PND1 PND2 PND3 PND
Naïve 6.7070.82 7.6970.70 9.1770.90 10.9
V 6.9170.89 7.8570.82 9.5070.94 11.2
Dex 6.8070.54 6.8970.49 7.1070.70n 8.1
DexCE 6.9570.76 7.2070.79 7.8071.06n 9.2
CE 6.9070.94 8.0071.04 9.2071.23 11.0
PND: postnatal day.
Data are reported as mean7S.D.
n Signiﬁcantly different from the Naïve, V, and CE groups at the same athe oxidative stress produced in the brain by the dexametha-
sone treatment (Camm et al., 2011). However, no information
is currently available regarding the effects of dexamethasone
combined with antioxidant vitamins on brain electrical activ-
ity. In this context, the use of CSD has also been employed to
study the actions of antioxidants on the brain (Abadie-
Guedes et al., 2008; Guedes et al., 2012; Monte-Guedes et al.,
2011).
The current in vivo study evaluated, in the albino rat, the
long lasting effects of neonatal dexamethasone, combined or
not with the administration of antioxidant vitamins C and E,
on changes in CSD features and LTP-like electrocorticogram
(ECoG)-potentiation associated with CSD.2. Results
2.1. Body weight
The ﬁve experimental groups did not differ with respect to
body weight on PND 1 and PND 2. From PND 3 to PND 6, rats
previously treated intraperitoneally with dexamethasone and
dexamethasone plus vitamins C and E (the Dex and DexCE
groups, respectively) exhibited lower body weight than
groups that were untreated (Naïve), vehicle-injected (V), and
treated with both vitamin C and vitamin E (CE). However, no
weight difference was observed when the pups reached PND
60 (Table 1).2.2. CSD parameters
The 1-min application of a cotton ball (1–2 mm diameter)
soaked with 2% KCl (approximately 270 mM) to a point of
the occipital cortical surface was very effective in eliciting a
single CSD episode that was propagated and sequentially
recorded at two points on the parietal cortex. This is illu-
strated in the recordings shown in Fig. 1.
Measurements of the amplitude and duration of the CSD
negative potential change revealed no intergroup difference;
the mean amplitudes ranged from 7.5071.45 mV to
8.2272.24 mV, and the mean durations ranged from 72.187
3.98 s to 75.1476.77 s (Table 2)., intraperitoneally injected with dexamethasone (Dex),
trol groups were injected only with the vehicles in which
e).
4 PND5 PND6 PND60
471.38 12.7071.87 14.9471.13 255.00722.69
071.32 12.5071.65 14.2871,73 240.30730.20
070.84n 8.9071.24n 10.2571.60n 246.94712.05
071.16n 10.3571.13n 11.7571.06n 244.44724.96
071.30 12.3571.83 14.0571.85 251.21716.77
ge (Po0.05; one-way ANOVA plus the Holm–Sidak test).
Fig. 1 – Electrocorticogram (ECoG) and slow potential change
(P) recordings during cortical spreading depression (CSD) in
ﬁve rats representative of the experimental groups: Naïve,
Vehicle, Dexamethasone (Dex), Dexamethasone plus
vitamins C and E (DexCE), and only vitamins C and E (CE).
The horizontal bars, which correspond to 1 min, show the
time of KCl application to elicit CSD at one occipital cortical
point in the right hemisphere. CSD elicitation by KCl was
repeated at intervals of 30 min. CSD propagation in the
occipital-to-frontal direction was monitored for 4 h at the
two recording points in the parietal region of the same
hemisphere. The bottom right skull diagram shows
recording positions 1 and 2 and the position of the reference
electrode (R), on the nasal bones, as well as the position of
the KCl stimulus. The vertical calibration bars indicate 5 mV
for the P recordings and 500 μV for the ECoG recordings
(negative upwards).
Table 2 – Amplitude and duration of the slow potential
change (P) during cortical spreading depression in young
adult rats (PND 60-70) distributed in ﬁve experimental
groups according to the previous (PND 1-6) hormonal and
antioxidant treatments: (1) Naïve control (Naïve); (2)
Vehicle control (V); (3) dexamethasone (Dex); (4) dexa-
methasone plus vitamins C and E (DexCE); and (5) control
with only vitamins C and E (CE).
CSD features
P amplitude (mV) P duration (s)
Naïve 7.5071,45 74.8078.56
V 8.2272.24 72.1873.98
Dex 7.7572.80 75.1476.77
DexCE 7.8472.24 74.6777.65
CE 7.7872.36 73.0976.33
Data are presented as mean7SEM of 9 CSD episodes elicited at
30-min intervals by 1-min 2% KCl application during the 4-h
recording period. There was no difference between the experi-
mental groups (one-way ANOVA).
Fig. 2 – Propagation velocities of cortical spreading
depression (CSD) in 60- to 70-day-old rats that previously
received no treatment (naïve group, n¼8), vehicle (V, n¼10),
dexamethasone (Dex, n¼10), dexamethasone with vitamins
C and E (DexCE, n¼9), or only vitamins C and E (CE, n¼10).
Data are presented as mean7SEM of nine CSD episodes
elicited during the 4-h recording period, at 30-min intervals,
by 1-min application of a cotton ball (1–2 mm diameter)
soaked in 2% KCl. nPo0.05 compared with the other groups
(ANOVA plus Holm–Sidak test).
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(4.14 mm/min70.22, n¼10) than the three control groups
(Naïve: 3.52 mm/min70.13, n¼8; V: 3.57 mm/min70.18,
n¼10; CE: 3.5170.24 mm/min, n¼10) (po0.05). Treatment
with Dex plus vitamins C and E (group DexCE) resulted in
CSD velocity (3.43 mm/min70.12, n¼9) comparable to that of
the controls (Fig. 2).
2.3. ECoG potentiation associated with CSD
In all groups, the amplitudes of the digitized ECoG (one 10-
min sample from each hour) during the baseline period were
compared with those of samples from the CSD period. The
ECoG amplitude became higher in the CSD period compared
with the baseline period (Fig. 3). Quantiﬁcation of ECoG
amplitudes revealed a CSD-related increase of approximately
50–60% (po0.05; paired t-test). Although the Dex groupexhibited a non-signiﬁcant trend toward displaying fewer
amplitude increases, no intergroup difference was observed
(Table 3).3. Discussion
In this study, we demonstrated for the ﬁrst time that treat-
ment with the glucocorticoid dexamethasone early in life
(PND 1–6) clearly accelerates CSD propagation, and the
coadministration of antioxidant vitamins with Dex counter-
acted that effect. Because the CSD acceleration was measured
when the animals were quite developed (PND 60–70), we
suggest that the effect of Dex on CSD propagation is perma-
nent, or at least long-lasting, as suggested regarding other
Fig. 3 – Examples of recordings of spontaneous cortical
activity (Electrocorticogram [E] and DC potential recordings
[P]) on the right hemisphere of ﬁve animals representative of
the ﬁve groups of this study, which show the potentiation of
electrocorticographic activity after cortical spreading
depression (CSD). Rats were treated with the vehicle used to
dilute dexamethasone and vitamin C (Vehicle, saline
solution), and vitamin E (Vehicle, olive oil), no treatment
(naïve), dexamethasone (Dex), vitamins C and E (CE), or
dexamethasone plus vitamins C and E (DexCE). For each
animal, comparison between the baseline recordings (left
traces) and the post-CSD recordings (right traces, taken after
a series of seven episodes of CSD) revealed the potentiation
of the electrocorticogram amplitude. The horizontal bars in
P1 traces indicate the period (1 min) during which
stimulation with 2% KCl was applied to the occipital region
of the same hemisphere to elicit CSD, which was recorded at
two parietal points 1 and 2 (see skull diagram in Fig. 1).
Vertical bars correspond to 5 mV in P and 0.5 mV in E
(negative upwards). The bottom-right time diagram of the
recording session indicates the time-points (rectangles
formed by interrupted lines) from which the baseline and
post-CSD recording samples were taken (respectively, left
and right rectangles). The beginning of the record, as well as
the ﬁrst and the last (9th) CSD episode are indicated in the
diagram by the vertical solid lines.
Table 3 – Increase of the electrocorticogram (ECoG)
amplitude after cortical spreading depression (CSD) in
developed rats (PND 60–70). ECoG was recorded for 2 h to
obtain a baseline value (before regular elicitation of CSD
was initiated), followed by 4 h of recording, during which
CSD was elicited at 30-min intervals. In each recording
hour, one 10-min recording sample was analyzed with
an algorithm implemented in MATLAB™. Data
(mean7SD) are presented as relative units (values of the
normalized amplitudes in relation to the lowest value,
which was considered equal to (1). Compared with the
baseline period, the amplitudes after CSD were signiﬁ-
cantly higher (Po0.05; paired t-tests) in all groups, as
indicated by the asterisks. There was no difference
between the experimental groups (one-way ANOVA).
EcoG amplitude (Relative units)
Before CSD After CSD
Naïve 1.0570.03 1.7170.20n
V 1.0670.04 1.7270.33n
Dex 1.0670.05 1.5070.23n
DexCE 1.0570.03 1.6870.37n
CE 1.0470.02 1.7070.42n
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2014; Vázquez et al., 2012). Mammalian brain development
largely occurs early in life, during the perinatal period. In the
rat, the lactation period is very sensitive to adverse environ-
mental and nutritional conditions (Morgane et al., 1978;
Smart and Dobbing, 1971). It has been demonstrated that
Dex exposure early in life can change brain morphology and
function in rodents, producing long-term effects (Ichinohashi
et al., 2013; Li et al., 2014; Vázquez et al., 2012).
Clinical and experimental studies show that early-life DEX
exposure exerts a lasting adverse effect on somatic growth
(Flagel et al., 2002; Shrivastava et al., 2000). In line with those
results, our DEX-treated rats weighed signiﬁcantly less thanthose of the control groups. This adverse effect may be
causally linked, at least in part, to inadequate nutritional
intake during the postnatal period, to the rise in tissue
catabolism, or to protein breakdown after Dex treatment
(Leitch et al., 1999; Neal et al., 2004). Interestingly, Dex
exposure during the late gestational period of the rat
enhances serum levels of the anorexic factor leptin, and
lowers the hypothalamic mRNA levels of the orexigenic factor
NPY in progeny (Iwasa et al., 2014). Wang and colleagues
(Wang et al., 2010) did not observe any differences in
maternal care between Dex-treated and vehicle-treated rats;
therefore, these authors argue that the somatic growth
deﬁcits observed in DEX-treated rat pups can hardly be
explained by differences in maternal care versus control
pups. This view is also supported by the present data.
CSD has been implicated in important neurological human
disorders, such as epilepsy, migraine, and traumatic brain
injury (Dreier et al., 2012; Noseda and Burstein, 2013; Torrente
et al., 2014a). Abnormal EEG activity, including seizures, is
commonly seen in preterm human newborns within 48 h of
premature birth, and is associated with adverse outcomes
(Hellström-Westas and Rosén, 2005; Logitharajah et al., 2009;
Shah et al., 2012). In adult rats, Dex can modulate status
epilepticus, resulting in better or worse outcome depending on
the experimental paradigm (Al-Shorbagy et al., 2012; Duffy
et al., 2014; Yılmaz et al., 2014). However, this issue has not
yet been addressed in developing rats. Thus, it is critical to
understand whether and how common clinical interventions,
such as neonatal glucocorticoid therapy, affect brain electri-
cal activity as the brain develops. Several studies have
suggested alternative therapeutic approaches that aim to
minimize the adverse effects of dexamethasone treatment
on the brain early in life. These include handling (Claessens
et al., 2012b), pharmacological manipulation of the serotoni-
nergic system (Nagano et al., 2012), use of statins (Tijsseling
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2010). In this context, antioxidant vitamins have been suc-
cessfully employed to attenuate Dex-related physiological
disturbances in both the cardiovascular system (Herrera
et al., 2010; Niu et al., 2013) and the nervous system (Camm
et al., 2011). The present data represent an experimental
contribution to that, mainly considering that the antioxidant
vitamins C and E reversed the CSD Dex effects.
Our ﬁndings using CSD can be explained by different
mechanisms. We suggest that the following four factors are
most likely involved, and deserve comment: oxidative stress,
the glutamatergic system, glial activity, and myelin content.
The most plausible hypothesis involves oxidative stress; evi-
dence suggests that glucocorticoid treatment increases the
production of ROS in cultured hippocampus and cerebral cortex
(McIntosh and Sapolsky, 1996), and decreases the activity of
cerebral antioxidant enzymes (McIntosh et al., 1998). Pandya
et al. (2007) emphasize that repeated exposure to Dex can
signiﬁcantly inﬂuence the oxidative energy metabolism of brain
mitochondria in young growing animals, as well as in adults.
Camm et al. (2011) demonstrated that neonatal Dex treatment
increases oxidative stress indexes in the cerebral cortex, and
that the coadministration of Dex and antioxidant vitamins C
and E minimizes them, in addition to reducing the loss of
neuronal mass induced by Dex treatment. Several reports
have related CSD to oxidation processes and/or antioxidant
factors in the brain (Guedes et al., 2012). In addition, it has been
observed (in accordance with our results) that oxidative stress
increases CSD propagation velocity, while antioxidants
decrease the velocity (Abadie-Guedes et al., 2008). It is impor-
tant to highlight that CSD may induce neuronal injury and cell
death in young rats from 25 to 35 days old (Jafarian et al., 2010;
Sadeghian et al., 2012), but not in adult rats (Nedergaard and
Hansen, 1988). At that early age, it is possible that Dex increases
these harmful effects, and antioxidant vitamins administered
during early life may protect the cerebral cortex against these
injuries. This possibility shall be investigated in future
experiments.
The glutamatergic system has an important role in brain
development and in the functioning and plasticity of the central
nervous system (McDonald and Johnston, 1990). It was reported
recently that neonatal Dex exposure produces behavioral
abnormalities in juvenile and adult mice by altering glutama-
tergic neurotransmission via the NMDA receptor, and an NMDA
receptor antagonist is able to counteract these Dex-induced
abnormalities in later life (Li et al., 2014). Therefore, we also
consider it reasonable to postulate that Dex-induced distur-
bances in glutamatergic neurotransmission may result in CSD
effects. Interestingly, endogenous release of excitatory amino
acids and their action on the NMDA receptor play an important
role in the initiation, propagation, and duration of CSD
(Marrannes et al., 1988; Zhou et al., 2013). Our group has
previously demonstrated a long-lasting facilitation of CSD in
rats treated with monosodium glutamate early in life
(Lima et al., 2013). Thus, it is tempting to suggest that Dex
treatment at early developmental stages may hyperactivate
NMDA receptors, contributing to the CSD acceleration that we
report here.
Considering that CSD propagation depends largely on the
ﬁnely balanced electrochemical equilibrium of interactionsbetween neurons and glia, as well as the extracellular milieu
(Martins-Ferreira et al., 2000), changes in the number and
activity of glial cells might be related to the increased CSD
propagation velocity in the present Dex-treated group.
Claessens et al. (2012a) reported that neonatal Dex treatment
causes signiﬁcant reductions in astrocyte number and den-
sity in the hippocampus and corpus callosum. Unemura et al.
(2012) also observed in in vitro and in vivo conditions that the
astrocyte number decreases after glucocorticoids are applied,
and suggest that this decrease occurs as a result of reduced
expression of the glucocorticoid receptor.
The propagation velocity of CSD correlates inversely with
cortical myelin content in rodents: whether toxic or autoim-
mune-induced, cortical demyelination accelerates CSD, while
genetically engineered hypermyelination (neuregulin-1 type I
transgenic mice) decelerates CSD (Merkler et al., 2009). There-
fore, it is reasonable to associate the increased CSD propagation
velocity in the Dex-treated group with the reduction of cortical
myelin content. In line with this association, Kim et al. (2013)
observed a decrease in myelin content and changes in the
oligodendrocyte morphology after administering 0.5 mg/kg/d
Dex on PND 1–3. However, hypomyelination was not observed
when a lower dose of Dex was used (Camm et al., 2011).
Additional studies are necessary to clarify the real role of
each of these hypotheses. Also, another interesting hypothesis
to be tested is the possible role played by cytokines, which
increase after CSD (Kunkler et al., 2004) and activate microglia
(Grinberg et al., 2011). The CSD-related increased production of
cytokines could be modiﬁed by the Dex and/or antioxidant
vitamin treatment, as employed in our study, and this must be
clariﬁed.
Changes in brain excitability also inﬂuence CSD propaga-
tion, lending support to the idea that CSD is a useful index of
brain excitability (Souza et al., 2011). Because CSD is an
excitability-related brain phenomenon, we evaluated the
LTP-like ECoG potentiation produced in the cortical tissue
by CSD propagation (Footitt and Newberry, 1998; Souza et al.,
2011). Signiﬁcant potentiation occurred in all groups, and no
intergroup difference was observed, although the Dex group
exhibited a non-signiﬁcant trend toward displaying less ECoG
potentiation. Interestingly, in vitro studies have provided
evidence that Dex treatment early in life impairs LTP in the
hippocampus, as well as memory processes (Kamphuis et al.,
2003; Lin et al., 2006; Wang et al., 2010). The non-signiﬁcant
trend in the Dex group may be explained not only by changes
in synaptic plasticity, but also via alteration of neuronal
activity, which contributes to hyperexcitability after CSD
(Ghadiri et al., 2012), and consequently to the present
observed increase in ECoG amplitude.
In conclusion, the present in vivo study in young rats
describes novel and enduring electrophysiological CSD effects
that are attributed to previous treatment with Dex and/or the
antioxidant vitamins C and E. The results allow us to draw
two conclusions. First, Dex treatment increases CSD propaga-
tion velocity in a long-lasting manner. Second, this effect
is abolished by concomitant treatment with vitamins C and
E. We suggest that Dex therapy in premature organisms
may beneﬁt from the coadministration of these antioxidant
vitamins concerning the adverse effects of glucocorticoids
on the brain, although the appropriate extrapolation from
Table 4 – Description of the treatments (intraperitoneal injections) given to the ﬁve experimental groups on postnatal days
(PND) 1 to 6.
Intraperitoneal injections
(PND1–PND3) (PND4–PND6)
1st Injection 2nd Injection 1st Injection 2nd Injection
Naïve – – – –
V 0.9% NaCl Olive oil 0.9% NaCl Olive oil
Dex Dex Olive oil 0.9% NaCl Olive oil
DexCE Dexþvitamin C Vitamin E Vitamin C Vitamin E
CE Vitamin C Vitamin E Vitamin C Vitamin E
Animals received no injections (Naïve), vehicle (V; saline in the ﬁrst injection and olive oil in the second injection), dexamethasone in the ﬁrst
injection and vehicle in the second injection (Dex), DexþVitamin C (ﬁrst injection) and Vitamin E (second injection), or only vitamins C and E
(in the ﬁrst and second injections, respectively). Dexamethasone was administered on PND 1 to 3, and was discontinued from PND 4 to 6.
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investigation.4. Experimental procedures
4.1. Animals
Forty-seven newborn male Wistar rats from litters of 8 to 9
pups were used in this study. The animals were handled in
accordance with the standards of the Ethics Committee for
Animal Research of our university, which comply with the
“Principles of Laboratory Animal Care” (NIH; Bethesda, USA).
Shortly after birth (PND 0), the pups were assigned to ﬁve
experimental groups according to the hormonal and antiox-
idant treatments applied: (1) Naive Control (N; without any
treatment); (2) Vehicle Control (V; injected only with vehicle
solution); (3) Dexamethasone (Dex); (4) dexamethasone with
vitamins C and E (DexCE); and (5) Control with Vitamins C
and E (CE). During the treatment period (PND 1–6), each rat
received two intraperitoneal injections daily (10 mL/g for each
injection) due to the different solubilities of dexamethasone
(dexamethasone-21-phosphate, disodium salt) and vitamin C
[L-ascorbic acid] (both dissolved in 0.9% NaCl) versus vitamin
E [(þ)-α-tocopherol] (dissolved in olive oil). The three drugs
were purchased from Sigma (St. Louis, MO, USA). Dexametha-
sone was administered on the three ﬁrst postnatal days in
tapering doses: 0.5 mg/kg (PND 1), 0.3 mg/kg (PND 2), and
0.1 mg/kg (PND 3). Vitamin C (200 mg/kg/day) and vitamin E
(100 mg/kg/day) were applied daily on PND 1–6 at ﬁxed doses,
as previously described (Herrera et al., 2010; Camm et al.,
2011; Williams et al., 2012; Niu et al., 2013). The vitamin
solutions were prepared daily, shortly before the injections.
Table 4 presents the experimental groups included in
this study.
After weaning (PND 21), the pups were housed in poly-
propylene cages (51.0 cm35.5 cm18.5 cm; 3–4 rats per
cage) with free access to water and commercial standard diet
(PRESENCE, Purina, Brazil). The animal room was under a
12-h/12-h light/dark cycle (lights on at 6:00 a.m.), and room
temperature was set at 2371 1C. Body weight was recorded
daily during the hormonal and antioxidant treatment (PND
1–6) and at PND 60.4.2. CSD recording
When the pups reached 60–70 days of age, they were
anesthetized with an intraperitoneal injection of 1000 mg/kg
urethane plus 40 mg/kg chloralose, and three trephine holes
were drilled on the right side of the skull. These holes were
aligned in the frontal-occipital direction and paralleled to the
midline. The recording session lasted 6 h; during the initial
2 h (baseline period), no CSD was elicited; during the last 4 h
(CSD period), CSD was elicited at 30-min intervals by applying
a cotton ball (1–2 mm diameter) soaked with 2% KCl solution
(approximately 270 mM) to the posterior hole drilled on the
occipital region for 1 min. The other two holes on the parietal
region served as recording sites. We simultaneously recorded
the DC slow potential change typical of CSD and the ECoG
(band pass ﬁlters: 1–35 Hz) using two Ag–AgCl Agar-Ringer
electrodes (one in each hole on the parietal region) against a
common reference electrode of the same type placed on the
nasal bones. The spontaneous cortical electrical activity
was ampliﬁed and digitized with an MP100 or MP150 system
(BIOPAC Systems, Inc, USA) and stored in an IBM-compatible
computer for further analysis. The amplitude and duration of
the typical CSD-negative DC potential change, as well as the
CSD propagation velocity, were calculated. One 10-min
recording sample of the digitized ECoG was selected per
recording hour, and the average ECoG amplitude was calcu-
lated with an algorithm implemented in MATLAB™ (The
MathWorks, Inc.). For each animal, ECoG amplitude data are
presented as relative units (values of the normalized ampli-
tudes in relation to the lowest sample value, which was
considered equal to 1).
During the entire recording period, rectal temperature
was maintained at 3771 1C by means of a heating blanket.
The electrodes’ positions and the gains of the ampliﬁers
remained unchanged throughout.4.3. Statistical analysis
For intergroup comparisons (body weight, amplitude, dura-
tion, velocity, and ECoG potentiation) data were analyzed by
one-way ANOVA, followed by the Holm–Sidak test. For
intragroup comparisons of the ECoG analysis (baseline versus
b r a i n r e s e a r c h 1 5 9 1 ( 2 0 1 4 ) 9 3 – 1 0 1 99CSD period) the paired t-test was used. Differences were
considered statistically signiﬁcant when Pr0.05.Acknowledgments
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